Gilenya was the first once-a-day pill approved to treat relapsing multiple sclerosis (MS). Approved for first-line use, Gilenya is a disease-modifying therapy (DMT) that offers freedom from injections, which may fit many patients’ lifestyles. Gilenya helps slow down the physical problems caused by RRMS and decreases the frequency of MS flare-ups (relapses).
Gilenya is the most prescribed oral once-daily DMT. In the US, approximately 73,000 patients have been exposed to Gilenya. Worldwide, Gilenya has been used to treat approximately 217,000 patients in both clinical trials and the post-marketing setting, with approximately 480,000 years of patient experience
* “these drugs are off-label, use is not indicated for the treatment of MS”